ArticleThe Journal of experimental medicine2012
Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor.
Article in The Journal of experimental medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 82 citations in OpenAlex.
- Pseudomonas aeruginosa 3-oxo-C12HSL-induced apoptosis involves bitter taste receptor T2R14 and the mitochondrial calcium uniporter.Cell calcium · 2026Article
- Immunoreceptor CD300a regulates ischemic tissue damage and adverse remodeling in the mouse heart and kidney.The Journal of clinical investigation · 2025Article
- Loss of NR2F6 Protects from Salmonella Typhimurium Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- CD300a: An Innate Immune Checkpoint Shaping Tumor Immunity and Therapeutic Opportunity.Cancers · 2025Review
- Evolutionary analysis of CD300A and CD300C paired receptors in primates.Frontiers in immunology · 2025Article
- Small molecules as ligands in the tuning of immune regulatory receptors.Frontiers in immunology · 2025Review
- Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders.Cell reports. Medicine · 2024Article
- Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies.Cancer biology & medicine · 2024Article
- GW0742 reduces mast cells degranulation and attenuates neurological impairments via PPARExperimental neurology · 2024Article
- Apoptotic cell clearance components in inflammatory arthritis.Immunological reviews · 2023Review
- Human IgMInternational journal of molecular sciences · 2023Article
- Review
- CD300b regulates intestinal inflammation and promotes repair in colitis.Frontiers in immunology · 2023Article
- CD300a Regulates Mouse Macrophage Functionality in Allergic Inflammation.International archives of allergy and immunology · 2023Article
- Inhibitory pattern recognition receptors.The Journal of experimental medicine · 2022Review
- Article
- CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis.Immunology · 2021Article
- Putting the brakes on phagocytosis: "don't-eat-me" signaling in physiology and disease.EMBO reports · 2021Review
- The Expression and Function of CD300 Molecules in the Main Players of Allergic Responses: Mast Cells, Basophils and Eosinophils.International journal of molecular sciences · 2020Review
- Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When a cell undergoes apoptosis, phosphatidylserine (PS) is exposed on the outer leaflet of the plasma membrane. PS acts as an "eat-me" signal to direct phagocytes expressing PS receptors to engulf the apoptotic cell. We recently reported that the immunoreceptor CD300a, which is expressed on myeloid cells, is a PS receptor. We show that CD300a does not facilitate macrophage phagocytosis of apoptotic cells. Instead, CD300a delivers an inhibitory signal in mast cells to suppress production of LPS-induced inflammatory cytokines and chemokines. After cecal ligation and puncture (CLP), when a large number of cells undergo apoptosis in the peritoneal cavity, CD300a-deficient peritoneal mast cells produced more chemoattractant and recruited more neutrophils than did wild-type (WT) mast cells. As a result, CD300a-deficient mice showed increased neutrophil recruitment and improved bacterial clearance in the peritoneal cavity, and survived longer than WT mice. Antibody blockade of CD300a-PS interactions improved bacterial clearance and extended survival of WT mice subjected to CLP. These results indicated that CD300a is a nonphagocytic PS receptor that regulates mast cell inflammatory responses to microbial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.